Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Several possible studies

Story checked

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease (opens in a new tab)

news-medical.net · 2026-09-26

Short answerEvidenceSource

Short answer

Several possible studies

No clear answer.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

European Commission grants marketing authorization for NEZGLYAL® (leriglitazone), the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD), a rare neurodegenerative disease

news-medical.net · 2026-09-26

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

Several studies could be the source of this story.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Open claim evidence
3

Search result

Several studies could fit.

More than one paper fits the article's details, and none fits well enough to single out. Checking claims against the wrong study would be worse than not checking them at all.

Related research

Research nearby

The papers it could be

Nearby papers when the source is unclear.

and 12 more considered

Then inspect each claim

Evidence layer

Claim by claim

What the story asserts. With no source study, there is nothing to check these against.

Claim 1 of 6Not checkedThe European Commission granted marketing authorization under exceptional circumstances for NEZGLYAL (leriglitazone).View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 2 of 6Not checkedNEZGLYAL (leriglitazone) is described as the first pharmacological treatment approved for cerebral adrenoleukodystrophy (cALD) in the European Union.View evidenceHide evidence

As statedfirst approved pharmacological treatment

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 3 of 6Not checkedThe approval is said to be based on results from the Phase 2/3 NEXUS1 study and additional real-world evidence from compassionate use programs.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 4 of 6Not checkedThe treatment is presented as an orally bioavailable, brain-penetrating, selective PPAR gamma agonist for male cALD patients aged 2-12 years with gadolinium-negative brain lesions.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 5 of 6Not checkedThe article says cALD is a rapidly progressing neurodegenerative disease with demyelinating brain lesions that can lead to acute neurological decline and death in three to four years.View evidenceHide evidence

As stateddeath in three to four years

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Claim 6 of 6Not checkedThe story notes that the development program continues with a completed enrollment in the CALYX2 Phase 3 trial in adult male cALD patients with Gd-enhancing lesions and an ongoing TREE3 Phase 2a trial in pediatric Rett syndrome.View evidenceHide evidence

Not checked

NewsLink could not identify one source study, so this claim was not compared against a paper.

Finally, the search trail

Method layer

No single source study was found.

NewsLink still surfaces nearby research so you can inspect the field instead of a single paper.

Nearby research

No exact source, but these papers are close.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Supporting health literacy and quality use of medicines in Australian CALD (culturally and linguistically diverse) and non-CALD consumers using a multiple methods approach

Crossref

Source (opens in a new tab)

And 10 more candidates considered.